Multifaceted immune dysregulation characterizes individuals at-risk for rheumatoid arthritis

被引:0
作者
Eddie A. James
V. Michael Holers
Radhika Iyer
E. Barton Prideaux
Navin L. Rao
Cliff Rims
Virginia S. Muir
Sylvia E. Posso
Michelle S. Bloom
Amin Zia
Serra E. Elliott
Julia Z. Adamska
Rizi Ai
R. Camille Brewer
Jennifer A. Seifert
LauraKay Moss
Saman Barzideh
M. Kristen Demoruelle
Christopher C. Striebich
Yuko Okamoto
Enkhtsogt Sainbayar
Alexandra A. Crook
Ryan A. Peterson
Lauren A. Vanderlinden
Wei Wang
David L. Boyle
William H. Robinson
Jane H. Buckner
Gary S. Firestein
Kevin D. Deane
机构
[1] Benaroya Research Institute,Division of Rheumatology
[2] University of Colorado Anschutz Medical Campus,Division of Immunology and Rheumatology
[3] Stanford University,Department of Chemistry and Biochemistry
[4] VA Palo Alto Health Care System,Division of Rheumatology, Department of Internal Medicine
[5] University of California,Department of Biostatistics and Informatics, Colorado School of Public Health
[6] San Diego,Department of Cellular and Molecular Medicine
[7] Janssen Research and Development,Division of Rheumatology
[8] Tokyo Women’s Medical University School of Medicine,undefined
[9] University of Colorado Anschutz Medical Campus,undefined
[10] University of California,undefined
[11] San Diego,undefined
[12] Allergy and Immunology,undefined
[13] University of California,undefined
[14] San Diego,undefined
来源
Nature Communications | / 14卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Molecular markers of autoimmunity, such as antibodies to citrullinated protein antigens (ACPA), are detectable prior to inflammatory arthritis (IA) in rheumatoid arthritis (RA) and may define a state that is ‘at-risk’ for future RA. Here we present a cross-sectional comparative analysis among three groups that include ACPA positive individuals without IA (At-Risk), ACPA negative individuals and individuals with early, ACPA positive clinical RA (Early RA). Differential methylation analysis among the groups identifies non-specific dysregulation in peripheral B, memory and naïve T cells in At-Risk participants, with more specific immunological pathway abnormalities in Early RA. Tetramer studies show increased abundance of T cells recognizing citrullinated (cit) epitopes in At-Risk participants, including expansion of T cells reactive to citrullinated cartilage intermediate layer protein I (cit-CILP); these T cells have Th1, Th17, and T stem cell memory-like phenotypes. Antibody-antigen array analyses show that antibodies targeting cit-clusterin, cit-fibrinogen and cit-histone H4 are elevated in At-Risk and Early RA participants, with the highest levels of antibodies detected in those with Early RA. These findings indicate that an ACPA positive at-risk state is associated with multifaceted immune dysregulation that may represent a potential opportunity for targeted intervention.
引用
收藏
相关论文
共 57 条
[1]  
Deane KD(2021)Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift Arthritis Rheumatol. 73 181-93
[2]  
Holers VM(2012)EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis Ann. Rheum. Dis. 71 638-41
[3]  
Gerlag DM(2013)Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease Arthritis Rheum. 65 2243-52
[4]  
Demoruelle MK(2003)Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis Arthritis Rheum. 48 2741-9
[5]  
Rantapaa-Dahlqvist S(2004)Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Arthritis Rheum. 50 380-6
[6]  
Nielen MM(2017)The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population Rheumatology 56 2229-36
[7]  
Gan RW(2015)Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study Ann. Rheum. Dis. 74 1659-66
[8]  
Rakieh C(2019)Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study Ann. Rheum. Dis. 78 179-85
[9]  
Gerlag DM(2019)Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol Trials 20 283-94
[10]  
Al-Laith M(2022)Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial Lancet 400 3161-72